Pretrial Clashes Intensify In Neurontin Off-Label MDL

Law360, New York (February 11, 2010, 6:55 PM EST) -- With a trial in multidistrict litigation over Pfizer Inc.'s alleged off-label marketing of Neurontin barely more than a week away, the drugmaker is seeking depositions related to a Web site owned by plaintiff Kaiser Foundation Health Plan Inc. that Pfizer argues actually touts the drug’s off-label uses.

In at least two separate deposition battles ahead of a Feb. 22 trial, Pfizer contends that Kaiser's health care Web site recommends a generic version of Neurontin for the very conditions Kaiser argues the epilepsy drug is ineffective at...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.